Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 9/20 | 0.49 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026476 | 1.00 | LSS (0.49) | LSSHTR2CHTR2AHTR7KEAP1 | |
| SCHEMBL5030115 | 0.89 | LSS (0.46) | LSSHTR2CHTR2AHTR7HTR2B | |
| SCHEMBL5030114 | 0.89 | LSS (0.46) | LSSHTR2CHTR2AHTR7HTR2B | |
| SCHEMBL5025632 | 0.88 | TAS2R14 (0.52) | LSSHTR2CHTR2AHTR7 | |
| SCHEMBL5025629 | 0.88 | TAS2R14 (0.52) | LSSHTR2CHTR2AHTR7 | |
| SCHEMBL6018934 | 0.88 | LSS (0.56) | LSSHTR2CHTR2AHTR7HTR2B | |
| SCHEMBL6018936 | 0.88 | LSS (0.56) | LSSHTR2CHTR2AHTR7HTR2B | |
| SCHEMBL5025552 | 0.86 | LSS (0.52) | LSSHTR2CHTR2AHTR7HTR2B | |
| SCHEMBL5025555 | 0.86 | LSS (0.52) | LSSHTR2CHTR2AHTR7HTR2B | |
| SCHEMBL6019428 | 0.86 | HTR2C (0.51) | LSSHTR2CHTR2AHTR7HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442791-B2 | Aminoalkylamide substituted cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1667962-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005028427-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | LSS, CYP51A1, CYP46A1 | LSS 1/4885HTR2C 3153/4885HTR2A 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.